RxDoctor Payments Data

David Ruiz, MD

Family Medicine · Pismo Beach, CANPI 1003826884

Payments from drug & device makers

$3,057in general payments, 2019–2025

Across 150 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$355
  • Boehringer Ingelheim$322
  • Novo Nordisk$313
  • Merck$246
  • Johnson & Johnson$238
  • AstraZeneca$194
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,052100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,057 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$131,313
Medicare patients
248
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$75,040
JanuviaSitagliptin Phosphate39$40,338
XareltoRivaroxaban43$39,323
JardianceEmpagliflozin47$34,061
MounjaroTirzepatide26$23,886
OzempicSemaglutide14$20,269
FarxigaDapagliflozin Propanediol21$16,891
TrulicityDulaglutide11$16,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,353
MyrbetriqMirabegron21$12,266
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$10,714
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,548
Ezetimibe148$4,212
Zolpidem Tartrate74$3,889
Atorvastatin Calcium423$3,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$355$77,97384 claims
Lilly USA, LLCMounjaro, Trulicity$142$40,54037 claims
MerckJanuvia$246$40,33839 claims
Johnson & JohnsonXarelto$238$39,32343 claims
Boehringer IngelheimJardiance$322$34,06147 claims
GSKTrelegy Ellipta, Anoro Ellipta$190$21,90134 claims
Novo NordiskOzempic$313$20,26914 claims
AstraZenecaFarxiga$194$16,89121 claims
Astellas Pharma US IncMyrbetriq$79$12,26621 claims
AbbVieSynthroid$151$3,51146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Pismo Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →